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Objective. To evaluate the association of Apolipoprotein E4 (ApoE4) in Alzheimer’s dementia (AD) with comorbid diabetes
mellitus (DM). Methods. The study included subjects with Alzheimer’s dementia (AD) (n = 209), individuals with non-
Alzheimer’s dementia (nAD) (n = 122), individuals with parental history of AD (f/hAD) (n = 70), and control individuals
who had normal cognitive functions and no parental history of dementia (NC) (n = 193). Dementia was diagnosed using
International Classiﬁcation of Diseases-10 revision (ICD-10) criteria. DM was assessed on the basis of self-report and/or use
of antidiabetic medications. ApoE genotyping was done using sequence-speciﬁc primer polymerase chain reaction. Results.A p o E 4
allele frequencies were highest among AD with comorbid DM (0.35) followed by AD without DM (0.25), nAD with DM (0.13),
nAD without comorbid DM (0.12), and NC (0.08). Frequency of ApoE4 in persons with f/hAD was 0.13. The association of AD
with co-morbid DM in ApoE4 carriers was more in comparison to NC with DM (OR = 5.68, P = 0.04). Conclusion. There is a
signiﬁcant association between AD with co-morbid DM and ApoE4 genotype.
1.Introduction
With the rapid change in the demographic proﬁle of India,
theprevalenceofchronicdiseasesoftheelderlylikedementia
and DM type 2 is increasing. In India, over 3.7 million
people aged 60 years and above suﬀer from dementia, pre-
dominantly of Alzheimer’s type. Assuming that the current
prevalence rate remains stable, these numbers are projected
to increase to 6.35 million by 2025 [1]. Studies from India
indicate that ApoE4 allele is signiﬁcantly associated with AD,
and it is a risk factor [2–5].
There has been a pandemic rise of DM especially among
Asian Indians. Currently 40.9 million Indians suﬀer from
DM, and this is projected to increase to 69.9 million by
2025 [6]. Genetic predisposition and environmental factors
interact to increase the risk of DM among Asian Indians.
DM type 2 which accounts for 90% of DM is predominantly
a polygenic disease with various loci identiﬁed at PGC-
1α, PC-1 (K121Q), IRS-2, MODY, and so forth [7]. Many
population-based cross-sectional studies [8]a n dp r o s p e c t i v e
studies [9–13] have indicated that DM or abnormal glucose
tolerance doubled the risk of AD (RR 1.37–2.27); though
others have not conﬁrmed this link [14]. Tripathi et al. [15],
in a study from Northern India, reported DM as a risk
factor for dementia; 33.3% of their sample with dementia
had diabetes compared to 9% of the controls (P<0.001).
Other reports from Asia conﬁrm the association between
DM and AD in ApoE4 carriers. Peila et al. [16] in a large
population-based study of Japanese American men found a
signiﬁcantassociationbetweenDM,AD,andApoE4carriers;
subjects with ApoE4 allele and DM had a relative risk of
5.5 for AD. Matsuzaki et al. [17] in a retrospective analysis2 International Journal of Alzheimer’s Disease
of autopsies found a very signiﬁcant positive association
between hyperglycaemia, AD neuropathology, and ApoE4
status (OR 38.9).
We conducted a hospital-based cross-sectional study
of dementia, to evaluate the interaction between AD and
diabetes, as a function of the ApoE4 allele status.
2. Methods
2.1. Sample. Consecutive persons with dementia attending
the Geriatric Clinic of the Department of Psychiatry in
National Institute of Mental Health and Neurosciences
(NIMHANS), Bangalore, and their consenting oﬀspring
wereinvitedtoparticipateinthisstudy.Thissampleispartof
a larger study of genetic and clinical correlates in dementia,
and details about evaluation have been reported earlier [2].
In this paper, the study sample (n = 594) included AD (n =
209), nAD (n = 122), f/hAD (n = 70), and NC (n = 193).
The nAD group consisted of vascular and mixed dementia
(n = 46), frontotemporal dementia (n = 30), Lewy body
dementia (n = 10), and other dementias (n = 36). Control
subjects included genetically unrelated and cognitively intact
age-matched subjects. The study was approved by the
Ethics Committee of NIMHANS, and informed consent
was collected prior to participation. All the subjects were
evaluatedusingastandardprotocolincludinggeneralclinical
evaluation, functional assessment (Everyday Abilities Scale
forIndia,EASI[18]),neuropsychologytesting(HindiMental
Status Examination, HMSE [19]), laboratory investigations
(haemogram, blood glucose levels), and genotyping and
imaging (MRI scans using a 1.5 or 3 Tesla machine; or CT
scan) whenever possible. Clinical evaluation was done by
trained psychiatric residents and the diagnosis of demen-
tia established using ICD-10 criteria. Further sub-typing
was done by a psychiatric/neurology consultant. Their co-
morbid DM was recorded based on laboratory results or self-
reports,beingonantidiabeticmedication.Otherparticipants
were assessed using the same methodology and protocol.
Ten millilitres of venous blood was collected, and DNA
was extracted using salting out method [20]. Polymerase
chain reaction (PCR) was performed using sequence-speciﬁc
primerPCRmethodology[21].Thepresenceof173-bpband
was indicative of the speciﬁc ApoE haplotype. The results
were corroborated with real-time PCR results for 10% of the
samples in every experiment.
2.2. Statistical Methods. We compared ApoE4 frequency and
DM status in AD, nAD, f/hAD, and NC. Statistical analysis
was done using R software [22]. Comparisons between vari-
ablesweredoneusingchi-squaretestforcategoricalvariables
and unpaired t-test for continuous variables. Fisher’s exact
test was used when any of the values in the contingency table
was less than 10. Odds ratios and P values were computed,
and statistical signiﬁcance was inferred if P<0.05.
3. Results
Based on the sample selection, AD, nAD, and the NC were
o l d e rt h a n6 0y e a r s( 6 1 .14 ±11.40 years; 61.73 ±12.41 years;
60.35±15.65 years, resp.). The AD, nAD, and NC group had
crossed the age at risk for onset of DM. Results show that
on average, 11.6% of our study group had developed DM.
However, the prevalence of DM diﬀered between the various
groups, being—17.7% of the AD, 13.9% of the nAD, 6.2% of
the NC, and 4.3% of the f/hAD (Table 1).
A p o E 4c a r r i e rr a t e si nA D( n = 98/209) were higher
than age-matched NC (n = 32/193) (P<0.0001, Table 1).
The diﬀerence in ApoE4 carrier status between AD with
comorbid DM and NC was signiﬁcant (P = 0.0001). ApoE4
allele frequencies were highest among AD with co-morbid
DM (0.35) followed by AD without DM (0.25), nAD with
DM (0.13), nAD without co-morbid DM (0.12), and NC
(0.08). The association of AD with co-morbid DM in ApoE4
carrierswasmoreincomparisontoNCwithDM(OR=5.68,
P = 0.04, Figure 1).
There were 17 individuals in this study who were ApoE4
homozygotes—14 AD, 2 nAD, and one f/hAD. Among the
14AD with homozygous ApoE4, 6 (42.8%) individuals were
receiving treatment for DM. In comparison, there were 84
AD who were ApoE4 heterozygotes, of whom only 14 had
DM (16.6%). Homozygous ApoE4 carriers had signiﬁcantly
greater comorbidity of DM and AD (P = 0.035).
4. Discussion
The present cross-sectional study evaluates the relationship
between ApoE4 status, AD and DM in a sample from
southern India. The study also conﬁrms the signiﬁcant
association between ApoE4 allele and AD in the Indian
population [2–5]. The ApoE4 frequency however was not
associated with the age of onset of AD, or the degree of
cognitive and functional ability as assessed by HMSE and
EASI.
The study also reiterates the increased association of AD
and DM (P = 0.0004) established by other studies [8–
13, 15]. Interestingly, AD individuals with DM were more
likely to be ApoE4 carriers compared to NC with DM (OR
5.68). The ApoE4 allele frequency was also signiﬁcantly high
in this group (0.35). The current study indicates a need to
evaluate the role of ApoE4 as a risk factor for DM in future.
Earlier research of ApoE4 as a risk factor for DM has yielded
inconsistent results. Study in Mexican Americans [23] did
notﬁndanydiﬀerenceinApoE4frequencybetweendiabetics
and nondiabetics. It is interesting to note that Xu et al. [10]
found a signiﬁcant association between borderline DM and
AD only in non-ApoE4 carriers. Assessment of the ApoE4
status in DM without AD in the Indian population would
be able to provide some clarity towards this. Individuals with
ApoE4 alleleif foundtohaveanincreasedrisk toDMintheir
middle age, the combined presence of ApoE4 and DM might
furtherincreasetheriskofADlater.Testingofthishypothesis
wasnotfeasibleinthepresentstudyasitwasacross-sectional
one from a Geriatric Clinic which caters to the needs of
elderly with dementia. A prospective controlled followup
study of the individuals with DM with and without ApoE4
allele into old age is needed to establish the implications of
this association of ApoE4, AD and DM.International Journal of Alzheimer’s Disease 3
Table 1: Clinical proﬁle and ApoE polymorphism in the study population.
Alzheimer’s
dementia (AD)
(n = 209)
Non-Alzheimer’s
dementia (nAD)
(n = 122)
Individuals with
parental history
of AD (f/hAD)
(n = 70)
Control
individuals with
no parental history
of dementia (NC)
(n = 193)
P value
(comparing
AD and NC)
P value
(comparing
nAD and NC)
Mean age in years 61.14 ±11.40 61.73 ±12.41 37.27 ±8.87 60.35 ±15.65 0.56++ 0.41++
M: F 105:104 75:47 51:19 114:79 0.076∗ 0.67∗
DM, n (%) 37 (17.7) 17 (13.9) 3 (4.3) 12 (6.2) 0.0004∗ 0.02∗
HMSE 12.71 ±7.60 14.19 ±8.19 30 ±13 0 ± 1 <0.0001++ <0.0001++
EASI 8.41 ±2.76 8.19 ±3.03 0 0 <0.0001++ <0.0001++
E2E2, n (%) 0 (0) 1 (0.8) 0 (0) 0 (0) 1+ 0.39+
E2E3, n (%) 11 (5.3) 11 (9) 5 (7.1) 23 (11.9) 0.017∗ 0.42∗
E3E3, n (%) 100 (47.8) 82 (67.2) 48 (68.6) 138 (71.5) <0.0001∗ 0.42∗
E2E4, n (%) 13 (6.2) 4 (3.3) 0 (0) 2 (1) 0.007+ 0.21+
E3E4, n (%) 71 (34) 22 (18) 16 (22.9) 30 (15.5) <0.0001∗ 0.56∗
E4E4, n (%) 14 (6.7) 2 (1.6) 1 (1.4) 0 (0) 0.0001+ 0.15+
Total ApoE4 carrier, n (%) 98 (46.9) 28 (23) 17 (24.3) 32 (16.6) <0.0001∗ 0.16∗
ApoE4 carrier with DM, n (%) 20 (9.6) 4 (3.3) 0 (0) 2 (1) 0.0001+ 0.21+
HMSE: Hindi Mental Status Examination (indicates level of cognitive function; highest score possible = 31).
EASI: Everyday Abilities Scale for India (indicates level of functional disability, highest score possible = 12).
P values calculated by unpaired t-test++, chi-square test∗,a n dF i s h e r ’ se x a c tt e s t +.
AD n = 209
Mean age (y) 61.14 ± 11.4
M: F 105: 104
HMSE 12.71± 7.6
AD 209
100% Control 193
100%
17.7%
46.9%
9.6% of AD
20.4% of E4/x∗
54.1% of DM∗∗
E4/x 98
Control  n = 193
Mean age (y) 60.35 ± 15.65
M: F 114: 79
HMSE 30 ± 1
DM 37
n = 20
1% of control
6.3% of E4/x∗
16.7% of DM∗∗
n = 2
6.2%
DM 12 16.6%
E4/x 32
Figure 1: Venn diagram representation of AD and controls with their component distribution. Odds ratio comparing DM occurrence in
ApoE4 carriers between AD and controls is 3.85 (P = 0.1∗). Odds ratio comparing ApoE4-positive DM subjects between AD and controls is
5.68 (P = 0.04∗∗).
Lack of prospective design, detailed assessment of DM
and other validating phenotypes of AD like neuropsy-
chological assessment, and imaging techniques for all the
subjects are the limitations of the study. Reasonable sample
size, methodological rigor in diagnostic assessment, and an
attempt to correlate two conditions of increasing concern in
India, that is, diabetes and AD in the context of ApoE4 allele
are the strengths of the work.
Translational aspect of this association if proven is very
important. IntheIndian context, prevalenceof diabetes ison
the rise. Lifestyle and diet control measures to prevent DM
in ApoE4-positive individuals especially with homozygosity4 International Journal of Alzheimer’s Disease
in middle age may modify/reduce the risk of Alzheimer’s
dementia.
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